Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACZ885 in Newly Diagnosed Type 1 Diabetes Mellitus
NCT01322321Phase 2Withdrawn
- Sponsor
- Novartis
- Start
- Mar 2011
- Primary completion
- Jun 2011
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial in type 1 diabetes mellitus (T1D) comparing ACZ885 Arm with Placebo Arm (2 arms). Primary endpoint: Change from baseline of stimulated C-peptide after a mixed meal tolerance test at 13 months. Planned start Mar 2011; status: withdrawn.
02
Drugs
canakinumab
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT01322321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01322321.